PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
25007187-1	2014	BACKGROUND: The aim of this study is to analyze polymorphisms in genes involved in 6-mercaptopurine detoxification (TPMT); methotrexate (MTX) metabolism including ABCB1 (or MDR1), ABCC2, SLC19A1 (or RFC1), and SLCO1B1; and the MTX effect mainly MTHFR and TYMS, and to assess whether these polymorphisms are predictors of treatment toxicity and/or MTX clearance.	Mercaptopurine	83-99	methylenetetrahydrofolate reductase	Homo sapiens	245-250	
23865834-4	2014	Patients with MTHFR 677TT and 677CT + 1298AC were associated with lower frequency of 6-MP and MTX dose reduction due to leukopenia (p < 0.05).	Mercaptopurine	85-89	methylenetetrahydrofolate reductase	Homo sapiens	14-19	
16614955-3	2006	The objective of this study was to verify, in a population of young patients with IBD, the presence of an association among mutations in the MTHFR gene, the incidence of IBD, and the risk of adverse events during the treatment with thiopurines azathioprine (AZA) or 6-mercaptopurine (6MP).	Mercaptopurine	266-282	methylenetetrahydrofolate reductase	Homo sapiens	141-146	
18987660-0	2009	Heterozygosity at the TPMT gene locus, augmented by mutated MTHFR gene, predisposes to 6-MP related toxicities in childhood ALL patients.	Mercaptopurine	87-91	methylenetetrahydrofolate reductase	Homo sapiens	60-65	
16614955-3	2006	The objective of this study was to verify, in a population of young patients with IBD, the presence of an association among mutations in the MTHFR gene, the incidence of IBD, and the risk of adverse events during the treatment with thiopurines azathioprine (AZA) or 6-mercaptopurine (6MP).	Mercaptopurine	284-287	methylenetetrahydrofolate reductase	Homo sapiens	141-146